Surgerii Wants a Slice of the Surgical Robot Market

Surgerii Robotics closes a $100M Series D to expand its single-port surgical robot into global markets, backed by Loyal Valley Capital

6 Apr 2026

Beijing's operating rooms have quietly become a testing ground for the next generation of surgical robotics. Surgerii Robotics, a Chinese medical-device firm, has closed a $100m Series D funding round led by Loyal Valley Capital, with further backing from Shanghai Healthcare Capital, V Star Capital, DNV Capital, and Hefei Industrial Investment. The money is earmarked for manufacturing expansion, regulatory filings in new markets, and clinical adoption abroad.

The company's flagship device, the SHURUI robot, performs urologic, gynecologic, general, and thoracoscopic procedures through a single incision rather than several. The approach, its proponents argue, reduces surgical trauma and shortens recovery times. Whether that claim holds up at scale remains a matter of clinical debate, but the commercial numbers are at least encouraging: the system has been deployed across more than 70 Chinese hospitals and used in over 3,000 procedures. Regulators in both China and Europe have approved it, the latter certification arriving in late 2025.

Europe is the immediate target. A training partnership with IRCAD, a French surgical education institute with a strong international reputation, will prepare local surgeons to use the platform ahead of broader rollout. That kind of institutional endorsement matters in a market where unfamiliar brands face deep scepticism from procurement committees and hospital administrators alike.

The timing is pointed. Medtronic has begun its first American surgeries using the Hugo robot; Johnson and Johnson is still awaiting FDA clearance for its Ottava system; and Intuitive Surgical, the long-dominant maker of the da Vinci platform, is pushing into cardiac procedures. The field is becoming crowded, and differentiation is hard to sustain. Single-port architecture is a genuine technical distinction, but whether it constitutes a durable competitive advantage, or merely a design preference, is not yet clear.

The global surgical-robotics market is projected to exceed $20bn by 2032, propelled by demand for minimally invasive care. For Surgerii's backers, the bet is that compact, versatile systems will resonate particularly well in European and Asia-Pacific hospitals, where budget constraints and physical space often limit what established Western platforms can offer.

That is a plausible thesis. Whether it survives contact with entrenched procurement relationships and the regulatory pace of multiple jurisdictions is another question altogether.